What Is the Average Age of an ICD Recipient?

The typical ICD recipient in the United States is in their late sixties. A large registry study using the National Cardiovascular Data Registry found a mean age of about 68 years among patients receiving either a standard ICD or a cardiac resynchronization therapy defibrillator (CRT-D). That number, though, is an average pulled across a remarkably wide range of patients, from teenagers with inherited heart rhythm disorders to octogenarians with advanced heart failure. Understanding who actually gets these devices and how age shapes both the decision and the outcome gives a fuller picture than a single number can.

Where the Average Comes From

The roughly 68-year mean age reflects the population that most commonly needs an ICD: people with weakened heart muscle, usually from coronary artery disease or heart failure, who are at risk of sudden cardiac death. The ICD Registry data showed that patients receiving a standard ICD had a mean age of 67.9 years, while those receiving a CRT-D (a combined device that also helps the heart pump more efficiently) averaged 68.4 years.¹ These averages are tightly clustered because the underlying disease process, heart failure with reduced pumping function, is overwhelmingly a condition of middle-aged and older adults.

Primary prevention accounts for the majority of ICD implants. That means the device is placed before a patient has ever had a life-threatening arrhythmia, based on indicators like a very low ejection fraction. Secondary prevention, where the device goes in after someone has already survived a dangerous rhythm or cardiac arrest, makes up a smaller share. Patients receiving ICDs for ischemic cardiomyopathy (heart failure caused by blocked coronary arteries) tend to be older and carry more additional health problems than those with non-ischemic cardiomyopathy, where the heart muscle weakens for other reasons.² Since ischemic disease is more common overall, it pulls the average age upward.

The Average Has Been Climbing

ICD recipients were not always this old on average. When the devices first gained wide use in the 1990s, most implants were for secondary prevention in relatively younger patients who had survived cardiac arrest. As landmark clinical trials demonstrated that ICDs could prevent death in broader groups of heart failure patients, the indications expanded to include primary prevention. That shift brought in a much larger pool of patients, many of them elderly, who qualified based on their ejection fraction alone. An analysis of U.S. implantation trends from 1993 through 2006 found that the age and burden of other illnesses among ICD recipients increased over that period, even as the total number of implants rose sharply.³

This shift matters because the older a patient population gets, the more the question changes from “will the ICD prevent sudden death?” to “will the patient live long enough for the ICD to make a difference?” That tension between device eligibility and competing health risks is central to modern ICD decision-making.

When the Recipient Is a Teenager or Young Adult

At the opposite end of the spectrum, ICDs go to children and young adults far more rarely, and for very different reasons. Instead of coronary artery disease, the indications in young people are typically congenital heart defects, inherited rhythm disorders like long QT syndrome or catecholaminergic polymorphic ventricular tachycardia, or cardiomyopathies that show up early in life. A European registry of subcutaneous ICDs in pediatric and young adult patients with congenital heart conditions reported a median age at implantation of just 15 years.⁴

A broader study looking at ICDs in patients with congenital heart disease, pediatric cardiomyopathy, and primary electrical disease found a median implantation age of 23 years, with a wide spread (the middle half of patients ranged from 15 to 38 years).⁵ The most common diagnoses in that group were transposition of the great arteries and tetralogy of Fallot, both congenital heart defects that can leave patients vulnerable to dangerous rhythms even after surgical repair.

Subcutaneous ICDs have been particularly appealing for younger patients because they avoid threading a wire through the veins and into the heart. In a matched comparison study of subcutaneous versus transvenous ICDs, the median age was 41, and women made up 40% of the cohort, a much younger and more female group than the general ICD population.⁶ That lower age reflects the fact that subcutaneous devices are often chosen specifically for younger patients who face decades of living with a device and want to avoid the long-term risks of having wires inside the heart.

Sex Differences in Age at Implant

Women make up a minority of ICD recipients overall, typically around a quarter to a third of implants depending on the registry. When they do receive devices, female patients tend to be younger and are less likely to have ischemic heart disease or a history of atrial arrhythmias compared with male recipients.⁷ The reasons for this gap are a mix of biology and practice patterns. Women develop coronary artery disease later in life than men on average, and multiple studies have shown that women who do meet ICD criteria are referred for the device less often. The underrepresentation of women in the landmark ICD trials has also contributed to uncertainty about how strongly the trial results apply to female patients.

Does Age Change How Much the ICD Helps?

This is the question that generates the most debate. The short version: ICDs fire appropriately at about the same rate regardless of whether the patient is 40 or 80, but older patients are more likely to die from something other than a sudden arrhythmia, which can blunt the survival benefit.

A study tracking ICD recipients across age groups found that mortality climbed steadily with age. Among primary prevention recipients, deaths ranged from about 2 per 100 person-years in the youngest group (18 to 49) to about 10 per 100 person-years in those 80 and older. Yet the rate of appropriate shocks, meaning the device correctly detected and treated a dangerous rhythm, did not differ significantly across age groups.⁸ In other words, the device kept doing its job regardless of age, but older patients were dying of heart failure, kidney disease, infections, and other conditions that the ICD could not help.

The DANISH trial, which focused specifically on patients with non-ischemic heart failure, provided some of the clearest evidence that age modifies the ICD’s value. Long-term follow-up showed that patients 70 and younger had lower death rates with an ICD compared to those without one, while patients over 70 saw no significant survival difference.⁹ A deeper analysis of the same trial found a linearly decreasing relationship between ICD benefit and age, with the greatest benefit in the youngest patients and essentially no measurable effect in those over 70.¹⁰

That said, a pooled analysis of five major clinical trials found that ICD recipients were less likely to die than non-recipients across all age groups, including those 75 and older, though the sample size in the oldest group was small.¹¹ The point estimates still favored the ICD in the elderly, but the certainty around those estimates was lower. The evidence, taken together, suggests that age alone does not erase the ICD’s benefit, but competing illnesses can gradually shift the balance so that the device prevents fewer years of life lost.

Complications Rise with Age

Implanting an ICD is a relatively low-risk procedure, but the risks are not evenly distributed. A study of more than 200,000 primary prevention ICD implants in the United States found that any adverse event or death within the hospital stay occurred in about 2.8% of patients under 65, rising steadily to about 4.5% in patients 80 and older. After adjusting for other health conditions, patients aged 75 and up still faced meaningfully higher odds of a complication compared to younger patients.¹²

Older patients also tend to have a higher rate of early complications after the device is placed, though one offsetting finding is that they actually experience fewer inappropriate therapies, meaning shocks delivered when no dangerous rhythm is present.¹³ Being younger than 70 has been identified as an independent predictor of inappropriate shocks, likely because younger patients have higher heart rates and are more prone to fast atrial rhythms like atrial fibrillation that the device can mistake for a dangerous ventricular arrhythmia.¹⁴

Psychological Impact and Quality of Life by Age

Living with a device that can shock you without warning takes a psychological toll, and that toll is not distributed equally. Younger ICD recipients are more likely to experience anxiety and depression than older ones. A large cohort study found that the probability of anxiety and depressive symptoms was associated with younger age, living alone, and having a history of heart attack or heart failure.¹⁵

Interestingly, though younger patients start from a worse baseline in terms of quality of life after getting the device, they also tend to improve the most over time. Data from the INTRINSIC RV trial showed that patients under 50 had the lowest quality-of-life scores initially but experienced the greatest improvement compared with older age groups.¹⁶ One plausible explanation is that younger patients have more life disruption to process at first (careers, physical activity, driving restrictions, the existential weight of being told your heart might stop), but they also have more capacity to adapt and more years ahead to benefit.

The emotional burden is not just about shocks. Many patients report ongoing anxiety about the possibility of a shock, even if they have never received one. This anticipatory anxiety can lead to avoidance of exercise, social withdrawal, and reluctance to drive, all of which affect quality of life in ways that do not show up in survival statistics.

Guidelines and the Question of Age Cutoffs

Despite the age-related patterns in outcomes, professional guidelines have consistently avoided setting an upper age limit for ICD implantation. As far back as 2005, the American College of Cardiology and the American Heart Association made ICDs a strong recommendation for many patients with heart failure and reduced ejection fraction regardless of age. Subsequent guideline updates emphasized that older age alone is not a reason to withhold an ICD, and that the decision should weigh comorbidities, procedural risk, and patient preferences.¹⁷

In practice, though, ICD use drops off considerably among the oldest patients. The absence of a formal age cutoff does not mean age is irrelevant. Clinicians weigh expected survival, frailty, and the patient’s own goals. An 82-year-old with well-controlled heart failure and few other health problems is a very different candidate from an 82-year-old with advanced kidney disease, diabetes, and limited mobility. The guidelines effectively punt the decision to shared decision-making between the physician and the patient, which means the conversation matters as much as the criteria on paper.

Cost-Effectiveness and Implant Age

ICDs are expensive devices, and the economics shift with patient age. A Markov model analysis of lifetime cost-effectiveness in a European population found that age at implantation was one of the most influential variables in determining whether the device represented a reasonable use of health-care resources.¹⁸ Younger patients have more years to benefit from the device, which spreads the cost over a longer period. Older patients may need fewer generator replacements (each replacement is a surgical procedure and a major cost driver) but also have fewer life-years to gain.

That said, an analysis using U.S. data found that the cost-effectiveness ratios for ICD therapy were actually similar between patients 75 and older and younger patients, rising only in those with multiple additional health conditions.¹⁹ The takeaway is that age alone does not make an ICD a poor investment, but the combination of advanced age and heavy comorbidity does make the value proposition weaker.

End-of-Life Considerations

One of the most underappreciated aspects of ICD care involves what happens as patients approach the end of life. The average age at ICD deactivation, when the device’s shock function is turned off, is around 76 to 77 years based on registry data from patients who underwent deactivation, the large majority of whom were male.²⁰ A striking finding from that data is that nearly a third of deactivations happened after the patient had already died, meaning the conversation about turning off the device never happened while the patient could participate.

As illness progresses to a terminal stage, the ICD’s role can flip from life-extending to life-complicating. Research has shown that as many as one in five ICD patients receive shocks in the final weeks of life, a scenario that causes significant physical and psychological suffering for both the patient and their family.²¹ These shocks are painful and, at that stage, medically futile. The device faithfully does what it was programmed to do, detecting and attempting to correct a fatal rhythm, but the patient’s underlying disease has progressed beyond the point where preventing a single arrhythmic event changes the trajectory.

Professional societies recommend that end-of-life planning discussions include the option to deactivate the ICD, but these conversations happen less often than they should. The gap between guideline recommendations and real-world practice on this point remains one of the more troubling patterns in device management, particularly as the ICD population continues to age.

Inappropriate Shocks Across the Age Spectrum

Inappropriate shocks, where the device delivers a painful jolt in response to a rhythm that was not actually dangerous, are one of the most feared complications of living with an ICD. A large study of over 4,000 ICD patients found that about 10% experienced at least one inappropriate therapy episode, with a mean of 1.8 episodes per affected patient over roughly four years of follow-up. The average age of patients who received inappropriate therapies was 61, and there was no significant difference in age between those receiving ICDs for primary versus secondary prevention.²²

Atrial fibrillation is the leading culprit. The heart’s upper chambers fire rapidly, and the ICD interprets the fast, irregular signals as a dangerous ventricular rhythm. Having a history of atrial fibrillation roughly doubled the risk of inappropriate shocks, and being under 70 was independently associated with about an 80% higher risk as well.²³ Modern programming strategies have reduced the frequency of inappropriate shocks compared with earlier device generations, but the problem has not been eliminated. For younger, more active patients, the combination of higher heart rates during exercise and a longer lifetime exposure to the device means this remains a meaningful concern.